(Q28377949)

https://api.crossref.org/works/10.1016%2FS0091-3057%2898%2900240-8

7 January 2021

The selective 5-HT2A receptor antagonist MDL 100,907 counteracts the psychomotor stimulation ensuing manipulations with monoaminergic, glutamatergic or muscarinic neurotransmission in the mouse--implications for psychosis

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2898%2900240-8

7 January 2021

The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2898%2900240-8

7 January 2021

D1 dopamine receptor--the search for a function: a critical evaluation of the D1/D2 dopamine receptor classification and its functional implications

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2898%2900240-8

7 January 2021

Antipsychotic agents antagonize non-competitive N-methyl-D-aspartate antagonist-induced behaviors

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2898%2900240-8

7 January 2021

Biochemical and behavioural properties of clozapine

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2898%2900240-8

7 January 2021

Ritanserin, a selective 5-HT2/1C antagonist, and negative symptoms in schizophrenia. A placebo-controlled double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2898%2900240-8

7 January 2021

Clozapine. A review of its pharmacological properties, and therapeutic use in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2898%2900240-8

7 January 2021

Effects of neuroleptics on phencyclidine (PCP)-induced locomotor stimulation in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2898%2900240-8

7 January 2021

Comparison of chlorpromazine, haloperidol and pimozide in the treatment of phencyclidine psychosis: DA-2 receptor specificity

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2898%2900240-8

7 January 2021

Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine and serotonin receptor subtype selective antagonists in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2898%2900240-8

7 January 2021

Recent advances in the phencyclidine model of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2898%2900240-8

7 January 2021

Amphetamine and apomorphine responses in the rat following 6-OHDA lesions of the nucleus accumbens septi and corpus striatum

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2898%2900240-8

7 January 2021

SB 242084, a selective and brain penetrant 5-HT2C receptor antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2898%2900240-8

7 January 2021

Effect of the NMDA receptor antagonist, MK-801, on locomotor activity and on the metabolism of dopamine in various brain areas of mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2898%2900240-8

7 January 2021

Risperidone in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2898%2900240-8

7 January 2021

The apparent antipsychotic action of the 5-HT2a receptor antagonist M100907 in a mouse model of schizophrenia is counteracted by ritanserin. (Rapid communication)

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2898%2900240-8

7 January 2021

Reversal of amphetamine-induced behaviours by MDL 100,907, a selective 5-HT2A antagonist.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2898%2900240-8

7 January 2021

Phencyclidine-induced head-weaving observed in mice after ritanserin treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2898%2900240-8

7 January 2021

Agonist and antagonist properties of benzazepine and thienopyridine derivatives at the D1 dopamine receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2898%2900240-8

7 January 2021

5-HT2 receptors exert a state-dependent regulation of dopaminergic function: studies with MDL 100,907 and the amphetamine analogue, 3,4-methylenedioxymethamphetamine

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2898%2900240-8

7 January 2021

The role of 5-HT2A receptors in antipsychotic activity

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2898%2900240-8

7 January 2021

Dopamine receptors and the dopamine hypothesis of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2898%2900240-8

7 January 2021

Psychotropic effects of ritanserin, a selective S2 antagonist: an open study

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2898%2900240-8

7 January 2021

Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2898%2900240-8

7 January 2021

Brain microdialysis and its application for the study of animal behaviour

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2898%2900240-8

7 January 2021